Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

World’s Only Super-Database for Pharmaceutical Use During Pregnancy

By Drug Discovery Trends Editor | January 22, 2015

Anick Bérard

Anick Bérard

Should a woman prescribed antidepressants continue taking them while pregnant? The question is fraught — her health and that of her unborn child is at stake. Yet research to help her and her doctor make that decision is incomplete.

The problem, said epidemiologist Anick Bérard, is that medical researchers must exclude pregnant women from drug trials to protect their babies. Whether it’s antidepressants, antibiotics or anti-migraine medications, “this potentially means that pregnant women have less evidence-based treatment than men and non-pregnant women,” she said. Bérard, a professor in the faculty of pharmacy at the Université de Montréal, aims to change that. She has built a super-database called the Quebec Pregnancy Cohort (QPC) that has already yielded crucial insights into drug use and health outcomes for both mothers and children.

The QPC links four databases containing information on pregnancies of women covered by Quebec’s provincial prescription drug insurance starting in 1997. It represents one-third of women of child-bearing age in the province.

The QPC is one of few such databases, and the only one to contain precise gestational ages. This means researchers can match drug exposures to stages of pregnancy.

“Timing is pivotal,” said Bérard. “Every week of pregnancy produces something different. At six to nine weeks of gestation for example, the heart is formed.”

But the province’s databases were built to help government keep track of payments to doctors and pharmacists, not to analyze drug use outcomes.

And so Bérard and her team have painstakingly validated the data in the QPC. For example, a particular database code may mean a woman was prescribed a drug, but it does not reveal whether she took it. So the team went back to women in the databases to ask if they indeed took the drug, and whether they did so as prescribed.

Codes for birth defects were similarly validated. If it indicated a child was born with a heart defect, researchers crossed-checked with hospital and medical records.

“When we study drugs and the risk of certain birth defects, we know it’s a real risk,” explains Bérard.

In 2005, Health Canada asked her to look into emerging research showing links between pregnant women taking an antidepressant called Paxil and heart defects in their babies.

In 2007, her team published a study based on QPC data showing that Paxil indeed increases the risk of heart defects, helping shape guidelines in Canada and the U.S. on the treatment of depression during pregnancy.

Other users of the QPC have included the U.S. Food and Drug Administration, international universities and pharmaceutical companies.

But long before these groups came knocking, Bérard was renowned for her research into drug use during pregnancy. In 2002, l’Université de Montréal lured her back to her hometown with an offer of a research chair in medications in pregnancy. At the time, she was a professor of epidemiology at the Albert Einstein College of Medicine in New York City, and before that, a research fellow at the Harvard School of Medicine in Boston.

Bérard, 48, is a new recipient of the Canada Foundation for Innovation’s (CFI) John R. Evans Leaders Fund, which she will use to update the QPC beyond its current timeframe of 1997 to 2009.

The award will pay for buying and validating information from provincial databases up to 2014. CFI funds research infrastructure, which often means hardware, but the QPC is a tool like any other: “As an epidemiologist, my machine is my cohort,” said Bérard.

Source: University of Montreal


Filed Under: Drug Discovery

 

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE